| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2013.11.002 |
| P698 | PubMed publication ID | 24295639 |
| P50 | author | Reinhard Dummer | Q32650033 |
| P2093 | author name string | Olivier Michielin | |
| Simone M Goldinger | |||
| Jeannine D Rinderknecht | |||
| Lada Mitchell | |||
| Lea Felderer | |||
| Luisa Veronese | |||
| Christian P Turtschi | |||
| Nina B Eggmann | |||
| Paul René Hilfiker | |||
| P433 | issue | 3 | |
| P921 | main subject | brain metastasis | Q1620196 |
| patient | Q181600 | ||
| P304 | page(s) | 611-621 | |
| P577 | publication date | 2013-11-29 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study | |
| P478 | volume | 50 |
| Q35820476 | A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. |
| Q36103432 | A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib |
| Q48461953 | A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma |
| Q28079359 | Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) |
| Q54977694 | BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. |
| Q38498046 | BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma |
| Q37090142 | BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis |
| Q28076667 | BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy |
| Q38625131 | BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. |
| Q48656930 | BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis |
| Q34667825 | BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. |
| Q57176317 | Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine |
| Q50043573 | Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases |
| Q91099817 | Brain metastases |
| Q38314890 | Brain metastasis and treatment |
| Q31010216 | Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications |
| Q39331752 | Challenges in the delivery of therapies to melanoma brain metastases |
| Q38548397 | Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. |
| Q40283801 | Clinical trials in melanoma patients with brain metastases |
| Q38777596 | Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma |
| Q39069585 | Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care |
| Q38844399 | Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update |
| Q26769870 | Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy |
| Q37447879 | Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs |
| Q91832432 | Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma |
| Q38233339 | Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue". |
| Q38940098 | Converting biology into clinical benefit: lessons learned from BRAF inhibitors |
| Q48109517 | Current chemotherapeutic regimens for brain metastases treatment |
| Q48347310 | Dabrafenib Therapy in 30 Patients with Melanoma Metastatic to the Brain: a Single-centre Controlled Retrospective Study in Hungary |
| Q36652790 | Dabrafenib in metastatic melanoma: a monocentric 'real life' experience |
| Q38737680 | Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. |
| Q56673276 | Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter |
| Q39229266 | Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). |
| Q47573654 | Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? |
| Q57578829 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours† |
| Q38775281 | Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. |
| Q38598521 | Evolving treatment options for melanoma brain metastases |
| Q36533041 | Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases |
| Q56889910 | Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab |
| Q39247421 | Immune Checkpoint Inhibitors for Brain Metastases |
| Q38721253 | Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives |
| Q38829087 | Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. |
| Q35916658 | Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. |
| Q31144246 | Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). |
| Q38823508 | Improving patient outcomes to targeted therapies in melanoma |
| Q33755862 | In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways |
| Q48618698 | Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib |
| Q44470914 | Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis |
| Q92524861 | Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma |
| Q90971217 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series |
| Q41677075 | LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases |
| Q87597521 | Leptomeningeal Metastases |
| Q44959749 | Management of intracranial melanomas in the era of precision medicine |
| Q64971747 | Management of metastatic cutaneous melanoma: updates in clinical practice. |
| Q26795510 | Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q58547833 | Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma |
| Q38766796 | Melanoma Brain Metastases: Current Areas of Investigation and Future Directions |
| Q28069421 | Melanoma Brain Metastasis: Mechanisms, Models, and Medicine |
| Q31098294 | Melanoma brain metastases : Treatment options |
| Q47379314 | Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy |
| Q38807942 | Melanoma central nervous system metastases: current approaches, challenges, and opportunities |
| Q48368625 | Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. |
| Q38618899 | Metastatic melanoma: prognostic factors and survival in patients with brain metastases. |
| Q38764364 | Molecular insights into melanoma brain metastases |
| Q38950577 | Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. |
| Q38631975 | Oral Targeted Therapies and Central Nervous System (CNS) Metastases |
| Q57291301 | Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive |
| Q48404885 | Pediatric intracranial primary anaplastic ganglioglioma |
| Q48217300 | Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance |
| Q42362521 | Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System |
| Q38257364 | Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues |
| Q40366752 | Profile of vemurafenib-induced severe skin toxicities |
| Q64118723 | Prolonged Response Induced by Single Agent Vemurafenib in a Spinal Ganglioglioma: A Case Report and Review of the Literature |
| Q54982136 | Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. |
| Q38973621 | RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt |
| Q41241880 | Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients |
| Q38918333 | Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases |
| Q41361546 | Repeated stereotactic radiosurgery for patients with progressive brain metastases. |
| Q92446544 | Response of metastatic glioma to vemurafenib |
| Q35124193 | Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. |
| Q33650820 | Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients |
| Q47185289 | Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. |
| Q48234725 | Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. |
| Q38738053 | Systemic therapies in the treatment of non-small-cell lung cancer brain metastases |
| Q38285931 | Systemic therapy of brain metastases. |
| Q30239901 | Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma |
| Q38650211 | Systemic therapy of metastatic melanoma |
| Q38235584 | Systemic treatment for BRAF-mutant melanoma: where do we go next? |
| Q38715328 | Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors |
| Q64118762 | Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature |
| Q39192200 | Targeted Treatment of Brain Metastases |
| Q38856722 | Targeted agents and immunotherapies: optimizing outcomes in melanoma |
| Q41268316 | Targeted therapies in melanoma |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q47861254 | Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma |
| Q64067749 | Targeting Molecular Pathways in Intracranial Metastatic Disease |
| Q38289478 | The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. |
| Q39002330 | The Treatment of Melanoma Brain Metastases |
| Q26744335 | The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib |
| Q38564085 | The future of targeted therapies for brain metastases |
| Q90474060 | The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q91740514 | The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis |
| Q36750637 | The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma |
| Q36243993 | The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial |
| Q38843111 | The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma |
| Q53827061 | Treatment of Brain Metastases. |
| Q38646117 | Treatment of Melanoma CNS Metastases |
| Q36023879 | Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting |
| Q98178296 | Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases |
| Q48519287 | Upfront targeted therapy for symptomatic melanoma brain metastases: paradigm changing? |
| Q54250000 | Use of vemurafenib in a patient unable to swallow whole. |
| Q38357122 | Vemurafenib for the treatment of BRAF mutant metastatic melanoma |
| Q34662717 | Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma |
| Q47899183 | Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? |
| Q86778391 | [Successful drug desensitization after vemurafenib-induced rash] |
| Q55069085 | [What's new in skin cancers?]. |
Search more.